

Sodium Hyaluronate

Class: Antirheumatic

Indications: Intra-articular injection: Treatment of pain in osteoarthritis in knee in patients who have failed nonpharmacologic treatment and simple analgesics (Euflexxa, Gel-One, Hyalgan, OrthoVisc, Supartz, Synvisc, Synvisc-One) or nonsteroidal anti-inflammatory drugs (NSAIDS)

Available dosage form in the hospital: 20 MG/2ML PFS, 20 MG/2ML VIAL

Dosage:

Osteoarthritis of the knee: Intra-articular:

- Euflexxa: Inject 20 mg (2 mL) once weekly for 3 weeks (total of 3 injections)
- Gel-One: Inject 30 mg (3 mL) once
- Hyalgan: Inject 20 mg (2 mL) once weekly for 5 weeks (total of 5 injections); some patients may benefit with a total of 3 injections
- Orthovisc: Inject 30 mg (2 mL) once weekly for 3-4 weeks (total of 3-4 injections)
- Supartz: Inject 25 mg (2.5 mL) once weekly for 5 weeks (total of 5 injections); some patients may benefit with a total of 3 injections
- Synvisc: Inject 16 mg (2 mL) once weekly for 3 weeks (total of 3 injections)
- Synvisc-One: Inject 48 mg (6 mL) once

Common side effect:

Neuromuscular & skeletal: Arthralgia

Cardiovascular: Blood pressure increased

Central nervous system: Fatigue

Pregnancy Risk Factor: Adverse events were not observed in animal reproduction studies. Safety for use in pregnant women has not been established.